Regencell Bioscience (RGC) has had the highest return since April 19, 2024 by a mid-cap US stock, returning 4,487.9%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 4,487.89% |
Kodiak Sciences (KOD) | 2,713.4% |
AXT (AXTI) | 1,539.46% |
Amylyx Pharmaceuticals (AMLX) | 1,316.16% |
Sezzle (SEZL) | 1,275.1% |
Palvella Therapeutics (PVLA) | 1,087.74% |
Adaptive Biotechnologies (ADPT) | 984.85% |
CareDx (CDNA) | 972.16% |
Rigetti Computing (RGTI) | 906.6% |
Aura Minerals Inc Common Shares (AUGO) | 892.61% |
GRAIL, LLC (GRAL) | 858.85% |
Dave (DAVE) | 854.28% |
Almonty Industries Inc Common Shares (ALM) | 798.12% |
Travere Therapeutics (TVTX) | 759.69% |
Solaris Energy Infrastructure (SEI) | 733.86% |
Erasca (ERAS) | 693.79% |
Axogen (AXGN) | 672.87% |
Planet Labs PBC (PL) | 671.43% |
Pulse Biosciences (PLSE) | 628.65% |
Hut 8 Corp Common Stock (HUT) | 595.39% |
Clover Health Investments (CLOV) | 584.13% |
Applied Digital (APLD) | 575.83% |
GeneDx (WGS) | 569.7% |
Porch (PRCH) | 526.71% |
Ondas (ONDS) | 518.28% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.